Clinical Oncologists Want New Formula For Determining 340B Eligibility

November 19, 2014 at 3:59 PM
The American Society of Clinical Oncologists (ASCO) says Congress and HHS' Health Resources and Services Administration (HRSA) should reform the 340B drug discount program by increasing transparency and accountability, and develop a new formula for determining what qualifies as a 340B entity in order to ensure the program is used for its original intent to incentivize care for the uninsured, underinsured and Medicaid patients regardless of care setting. ASCO, as part of a broader set of Medicaid reform proposals released...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.